Bayer Braces for a Summer of Judicial and Financial Crossroads

Bayer faces €5B litigation cash outflow by mid-2026, a Supreme Court ruling on Roundup, and activist demands for a structural break-up, with stock near €37.

The pharmaceutical-to-agrochemical giant is staring down two defining legal moments that will shape its balance sheet for years. By mid-2026, the company expects a cash outflow of roughly €5 billion tied to litigation, pushing free cash flow as deep as minus €2.5 billion. Net debt is forecast to climb to €33 billion by year-end, forcing management to lean on stronger revenue from its agricultural and consumer-health divisions to offset a weaker pharmaceutical unit and keep the ship steady.

Legal Progress in Missouri, but the Clock Is Ticking

A federal judge in St. Louis has cleared a key hurdle for Bayer’s proposed $7.25 billion settlement covering future glyphosate claims. US District Judge Henry Edward Autrey rejected a bid to move the case to California, preserving a single forum for the class-action deal. The final hearing on whether to approve the settlement is set for 9 July 2026. If the judge gives the green light, the financial risk from new Roundup lawsuits will drop dramatically.

Yet that milestone is sandwiched between an even weightier decision. The US Supreme Court is expected to rule by the end of June on the so-called Durnell case, which asks whether a company can be found liable under state law when the federal Environmental Protection Agency has deemed the product safe. A favourable ruling would neutralise most of the roughly 65,000 outstanding claims. A negative one would reignite the litigation wave and, according to Jefferies analyst Michael Leuchten, could send the stock back to €30.

Market Reaction Muted After Initial Jump

Shares initially popped nearly 5% on Wednesday after the Missouri court decision, but the gain quickly faded. On Thursday the stock edged down 1.15% to €37.08, still clinging just above the 200-day moving average of €36.17. Year to date, Bayer’s equity is roughly 2.5% in the red. Jefferies maintains a “Hold” rating with a €40 target, cautioning that the legal picture remains incomplete until both the Supreme Court and the Missouri settlement hearing are resolved.

Meanwhile, a prominent institutional backer has quietly trimmed its exposure. Goldman Sachs reduced its voting rights stake to 4.89%, signalling that even patient money is waiting for clarity.

Shareholders Demand a Structural Break-Up

Beyond the courtroom, activist pressure is mounting. Large institutional investors are calling on Bayer to conduct an open-ended review of its conglomerate structure. Deka fund manager Ingo Speich wants a genuine debate on the group’s future once initial legal victories are secured, dismissing cosmetic changes. DWS’s Hendrik Schmidt opposes a piecemeal separation and insists that any demerger of the consumer-health division must involve a full placement of all shares in Germany.

Chief Executive Bill Anderson is defending his strategy. The restructuring is already in full swing: Bayer has cut roughly 14,000 jobs since the overhaul began, including more than 4,700 last year alone. Anderson argues that operational efficiency, not a break-up, is the right path.

A Regulatory Tailwind from Europe

On the regulatory front, Bayer picked up an unexpected boost. The European Parliament voted on Thursday to loosen rules on new genomic techniques, allowing minor genetic modifications in plants to bypass special labelling. Crucially, patents on such seeds will remain permitted, opening fresh growth avenues for Bayer’s crop-science unit. The new framework is expected to take effect around mid-2028.

With the US Supreme Court decision due within weeks and the Missouri settlement hearing on 9 July, Bayer’s management is navigating a narrow corridor between €5 billion in projected cash outflows and the chance to cap a multi-billion-dollar liability. The next month will determine whether the stock holds its ground near the 200-day line or slides toward the bear-case target of €30.